Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2024 | The efficacy of olutasidenib in AML following venetoclax failure

Jorge Cortes • 1 Jun 2024
EHA 2024
Acute Myeloid Leukemia Leukemia Azacitidine Olutasidenib Venetoclax

Jorge Cortes, MD, Georgia Cancer Center, Augusta University, Augusta, GA, discusses the safety and efficacy of olutasidenib, an IDH inhibitor, in patients with acute myeloid leukemia (AML) who experience venetoclax failure. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Jorge Cortes

Incorporating patient goals into frontline TKI selection in CML
2:17
Incorporating patient goals into frontline TKI selection in CML
Jorge Cortes • 10 Sep 2026
Optimizing frontline therapy selection to prevent resistance in CML
1:58
Optimizing frontline therapy selection to prevent resistance in CML
Jorge Cortes • 10 Sep 2026
Managing patients with CML and additional genetic abnormalities
1:34
Managing patients with CML and additional genetic abnormalities
Jorge Cortes • 10 Sep 2026
Where does the treatment landscape for managing frontline CML currently stand?
1:44
Where does the treatment landscape for managing frontline CML currently stand?
Jorge Cortes • 10 Sep 2026

Related Videos

How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
2:00
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
Alexey Danilov • 16 Oct 2026
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
3:39
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
Marta Coscia • 16 Oct 2026
CaDAnCe-101 trial: exploring the potential of tacabrutideg, a novel BTK degrader, in R/R CLL/SLL
4:56
CaDAnCe-101 trial: exploring the potential of tacabrutideg, a novel BTK degrader, in R/R CLL/SLL
Stephan Stilgenbauer • 16 Oct 2026
Continuous acalabrutinib versus acalabrutinib plus venetoclax in del(17p) or TP53-mutated CLL
1:22
Continuous acalabrutinib versus acalabrutinib plus venetoclax in del(17p) or TP53-mutated CLL
Marta Coscia • 16 Oct 2026
The content of VJHemOnc is intended for healthcare professionals